羧甲司坦口服溶液联合重组人干扰素α1b治疗小儿急性喘息性支气管炎的效果

Effect of Carboxymesteine Oral Solution Combined with Recombinant Human Interferon c1b in the Treatment of Acute Asthmatic Bronchitis in Children

目的分析急性喘息性支气管炎患儿接受重组人干扰素α1b单药与联合羧甲司坦口服溶液治疗的效果。方法回顾性分析2021年6月至2023年6月医院收治的100例急性喘息性支气管炎患儿资料,按不同治疗方案分为对照组、观察组,各50例。对照组接受重组人干扰素α1b治疗,观察组接受羧甲司坦口服溶液联合重组人干扰素α1b治疗。比较两组临床疗效、主要症状缓解时间、气道炎症相关因子[趋化因子配体3(CCL3)、高迁移率族蛋白B1(HMGB1)、α1-酸性糖蛋白(α1-AG)]、T淋巴细胞(CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+))及不良反应。结果观察组临床总有效率高于对照组(P<0.05)。治疗后观察组气促、喘息、咳嗽、肺部音等症状缓解时间降低(P<0.05)。治疗4、7 d后,两组CCL3、HMGB1、α1-AG较治疗前下降,且观察组低于对照组(P<0.05);两组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)较治疗前升高,且观察组高于对照组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论羧甲司坦口服溶液联合重组人干扰素α1b治疗急性喘息性支气管炎,可抑制气道炎症,调节机体免疫,促进症状缓解,疗效确切,且安全性高。

Objective To analyze the therapeutic effects of recombinant human interferonα1b monotherapy and combined carboxymesteine oral solution in children with acute asthmatic bronchitis.Methods The data of 100 children with acute asthmatic bronchitis in hospital from June 2021 to June 2023 were retrospectively analyzed and divided into control group and observation group with 50 cases in each group according to different treatment plans.The control group was treated with recombinant human interferonα1b,and the observation group was treated with carboxymesteine oral solution plus recombinant human interferonα1b.The clinical efficacy,duration of major symptom remission,airway inflammation related factors[chemokine 3(CCL3),high mobility group protein B1(HMGB1),α1-acidic glycoprotein(α1-AG)],T lymphocytes(CD3^(+),CD4^(+),CD4^(+)/CD8^(+))and adverse reactions were compared between the two groups.Results The total effective rate of observation group was higher than that of control group(P<0.05).After treatment,the relief time of symptoms such as shortness of breath,wheezing,cough and pulmonary rales was reduced in the observation group(P<0.05).After 4 and 7 days of treatment,CCL3,HMGB1 andα1-AG in both groups were significantly decreased compared with before treatment,and the observation group was lower than the control group(P<0.05).After 4 and 7 days of treatment,CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in both groups were significantly higher than before treatment,and the observation group was higher than the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Carboxymesteine oral solution combined with recombinant human interferonα1b in the treatment of acute asthmatic bronchitis can inhibit airway inflammation,regulate body immunity,accelerate symptom relief,with significant efficacy and high safety.